ClinicalTrials.gg
CompletedNCT03311412Updated May 30, 2023

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

A Phase 1 interventional study of Sym021 and Sym022 in Metastatic Cancer, Solid Tumor and Lymphoma, sponsored by Symphogen A/S. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-30.

Sponsored by Symphogen A/S · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Mar 2022, 4 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
89
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,057 studies in Neoplasm Metastasis with a site in United States — 344 open to participants now, 544 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Enrollment
576th of 1,866
89 · median 43
Started
2017
with 79 others
Phase 1
710 of 2,057
127 open now
Registered
1,209th of 2,057
by date

Among the 2,057 studies in Neoplasm Metastasis with a site in United States, this one is the 576th largest by enrollment of the 1,866 interventional ones that give a count, is one of 80 that started in 2017, is one of 710 in phase 1, and was the 1,209th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

344 of the 2,057 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

339 more — sign in →

All 344 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,057 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to see if Sym021 is safe and tolerable as monotherapy, in combination with either Sym022 or Sym023, and in Combination with both Sym022 and Sym023 for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.

Read the detailed description

Part 1 of this study will evaluate the safety, tolerability, and dose-limiting toxicities (DLTs) to establish the maximum tolerated dose (MTD) and/or the selected dose of sequential escalating doses of Sym021 when administered once every 2 weeks (Q2W) by IV infusion to patient cohorts with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available

Part 2 of the study will evaluate the safety, tolerability, and DLTs to establish the MTD and/or the selected dose of sequential escalating doses of Sym022 when administered Q2W in combination with a fixed dose of 3 mg/kg of Sym021, each by IV infusion to patient cohorts with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available

Part 3 of the study will evaluate of the safety, tolerability, and DLTs to establish the MTD and/or the selected dose of sequential escalating doses of Sym023 when administered Q2W in combination with fixed doses of 3 mg/kg of Sym021 and either 1, 3 or 5 mg/kg of Sym022, each by IV infusion to patient cohorts with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.

03

Conditions studied

  • Metastatic Cancer
  • Solid Tumor
  • Lymphoma

Keywords

  • Locally advanced/unresectable
  • Metastatic solid tumor
  • Lymphoma
  • Anti-PD-1
  • PD-1
  • PD1
  • Anti-LAG-3
  • LAG-3
  • LAG3
  • Anti-TIM-3
  • TIM-3
  • TIM3
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients, ≥ 18 years of age at the time of obtaining .
  • Documented (- or cytologically-proven) solid tumor that is locally advanced or ; patients with documented lymphoma.
  • Malignancy (solid tumor or lymphoma) that is currently not amenable to surgical intervention due to either medical or non-resectability of the tumor.
  • to or intolerant of existing therapy(ies) known to provide clinical benefit.
  • Measurable or non- according to v1.1 or RECIL 2017.
  • (ECOG) performance status (PS) of 0 or 1.
  • Persons of agreeing to use a highly effective method of during the study beginning within 2 weeks prior to the first dose and continuing until 6 months after the last dose of study drug(s); men agreeing to refrain from sperm donation during this period.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or intending to become pregnant before, during, or within 6 months after the last dose of study drug; women who are breastfeeding; persons of and not willing to use a highly effective method of .
  • Central nervous system (CNS) ; patients with known, untreated CNS or , or spinal cord compression, patients with any of the above not controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS involvement for which treatment is required.
  • Hematologic malignancies other than lymphoma.
  • Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to Cycle 1/Day 1 (C1/D1) unless adequately treated and considered stable.
  • Active uncontrolled bleeding or a known bleeding diathesis.
  • cardiovascular disease or condition.
  • Significant ocular disease or condition, including history of an or inflammatory disorder.
  • Significant pulmonary disease or condition.
  • Current or recent (within 6 months) significant gastrointestinal (GI) disease or condition.
  • An active, known, or suspected autoimmune disease, or a documented history of autoimmune disease or syndrome, requiring systemic or other medications.
  • History of organ transplantation (e.g., stem cell or solid organ transplant).
  • History of significant toxicities associated with previous administration of that necessitated permanent discontinuation of that therapy.
  • Patients with unresolved > Grade 1 toxicity associated with any prior antineoplastic therapy except for persistent Grade 2 alopecia, peripheral neuropathy, decreased , lymphopenia, hypomagnesemia, and/or end-organ failure being adequately managed by hormone replacement therapy.
  • Inadequate recovery from any prior surgical procedure, or having undergone any major surgical procedure within 4 weeks prior to C1/D1.
  • Known history of (HIV) or known active infection with virus (HBV) or virus (HCV).

Drugs and Other Treatments Exclusion Criteria:

  • Part 2 Combination Dose-Escalations ONLY: Prior therapy with:

    • Sym021 or other inhibitors of PD-1/PD-L1.
    • Sym022 or other inhibitors of LAG-3, if participating in Arm A.
    • Sym023 or other inhibitors of TIM-3, if participating in Arm B.
  • Part 3 Combination Dose-Escalations ONLY: Prior therapy with:

    • Sym022 or other inhibitors of LAG-3
    • Sym023 or other inhibitors of TIM-3
  • Any antineoplastic agent for the primary malignancy (standard or ) within 4 weeks or 5 plasma half-lives, whichever is shortest, prior to first study drug administration and during study, with exceptions.
  • Any other investigational treatments within 2 weeks prior to and during study; includes participation in any medical device or supportive care therapeutic intervention trials.
  • Radiotherapy, with exceptions.
  • Use of against infectious diseases 4 weeks prior to first study drug administration and during study.
  • Immunosuppressive or systemic hormonal therapy within 2 weeks prior to first study drug administration and during study, with exceptions.
  • Prophylactic use of hematopoietic growth factors within 1 week prior to first study drug administration and during Cycle 1 of study.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    Sym021 Dose Level 1

    Part 1, Sym021 monotherapy dose level 1

    Drug: Sym021

  • Experimental
    Sym021 Dose Level 2

    Part 1, Sym021 monotherapy dose level 2

    Drug: Sym021

  • Experimental
    Sym021 Dose Level 3

    Part 1, Sym021 monotherapy dose level 3

    Drug: Sym021

  • Experimental
    Arm A: Sym021+Sym022 Dose Level 1

    Part 2, Arm A: Sym021 RP2D in combination with dose level 1 of Sym022

    Drug: Sym021 · Drug: Sym022

  • Experimental
    Arm A: Sym021+Sym022 Dose Level 2

    Part 2, Arm A: Sym021 RP2D in combination with dose level 2 of Sym022

    Drug: Sym021 · Drug: Sym022

  • Experimental
    Arm A: Sym021+Sym022 Dose Level 3

    Part 2, Arm A: Sym021 RP2D in combination with dose level 3 of Sym022

    Drug: Sym021 · Drug: Sym022

  • Experimental
    Arm A: Sym021+Sym022 Dose Level 4

    Part 2, Arm A: Sym021 RP2D in combination with dose level 4 of Sym022

    Drug: Sym021 · Drug: Sym022

  • Experimental
    Arm B: Sym021+Sym023 Dose Level 1

    Part 2, Arm B: Sym021 RP2D in combination with dose level 1 of Sym023

    Drug: Sym021 · Drug: Sym023

  • Experimental
    Arm B: Sym021+Sym023 Dose Level 2

    Part 2, Arm B: Sym021 RP2D in combination with dose level 2 of Sym023

    Drug: Sym021 · Drug: Sym023

  • Experimental
    Arm B: Sym021+Sym023 Dose Level 3

    Part 2, Arm B: Sym021 RP2D in combination with dose level 3 of Sym023

    Drug: Sym021 · Drug: Sym023

  • Experimental
    Arm B: Sym021+Sym023 Dose Level 4

    Part 2, Arm B: Sym021 RP2D in combination with dose level 4 of Sym023

    Drug: Sym021 · Drug: Sym023

  • Experimental
    Arm B: Sym021+Sym023 Dose Level 5

    Part 2, Arm B: Sym021 RP2D in combination with dose level 5 of Sym023

    Drug: Sym021 · Drug: Sym023

  • Experimental
    Sym021+Sym022+Sym023 Dose Level 1

    Part 3, Sym021 in combination with Sym022 and Sym023

    Drug: Sym021 · Drug: Sym022 · Drug: Sym023

  • Experimental
    Sym021+Sym022+Sym023 Dose Level 2

    Part 3, Sym021 in combination with Sym022 and Sym023

    Drug: Sym021 · Drug: Sym022 · Drug: Sym023

  • Experimental
    Sym021+Sym022+Sym023 Dose Level 3

    Part 3, Sym021 in combination with Sym022 and Sym023

    Drug: Sym021 · Drug: Sym022 · Drug: Sym023

  • Experimental
    Sym021+Sym022+Sym023 Dose Level 4

    Part 3, Sym021 in combination with Sym022 and Sym023

    Drug: Sym021 · Drug: Sym022 · Drug: Sym023

  • Experimental
    Sym021+Sym022+Sym023 Dose Level 5

    Part 3, Sym021 in combination with Sym022 and Sym023

    Drug: Sym021 · Drug: Sym022 · Drug: Sym023

Interventions

  • DrugSym021

    Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.

    Also known as: Anti-PD-1

  • DrugSym022

    Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.

    Also known as: Anti-LAG-3

  • DrugSym023

    Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.

    Also known as: Anti-TIM-3

06

What researchers measure

Primary outcomes

  1. Part 1: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria.

    Assess the safety and tolerability of Sym021 monotherapy on a Q2W schedule. Assessment based on the occurrence of AEs meeting DLT criteria measured during Cycle 1.

    Time frame: 12 months

  2. Part 2: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria.

    Assess the safety and tolerability of the Sym021 RP2D in combination with sequential escalating doses of Sym022 or Sym023 on a Q2W schedule. Assessment based on the occurrence of AEs meeting DLT criteria measured during Cycle 1.

    Time frame: 12 months

  3. Part 3: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria.

    Assess the safety and tolerability of the Sym021 RP2D in combination with sequential escalating doses of Sym022 and Sym023 on a Q2W schedule. Assessment based on the occurrence of AEs meeting DLT criteria measured during Cycle 1.

    Time frame: 12 months

Secondary outcomes

  1. Evaluation of the immunogenicity of Sym021 as a single agent and in combination with Sym022 and Sym023.

    Serum sampling to assess the potential for anti-drug antibody (ADA) formation.

    Time frame: 24 months

  2. Evaluation of objective response (OR) or stable disease (SD).

    Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), Response Evaluation Criteria in Lymphomas 2017 (RECIL 2017), or Immunotherapeutics Response Evaluation Criteria in Solid Tumors (iRECIST), depending on tumor type.

    Time frame: 24 months

  3. Time to progression (TTP) of disease.

    Based on time of enrollment to first evidence of progression on imaging studies, as assessed by RECIST v1.1, RECIL 2017, or iRECIST, depending on tumor type.

    Time frame: 24 months

  4. Area under the concentration-time curve in a dosing interval (AUC)

    Will be estimated using non-compartmental methods and actual timepoints.

    Time frame: 24 months

  5. Maximum concentration (Cmax)

    Will be derived from observed data.

    Time frame: 24 months

  6. Time to reach maximum concentration (Tmax)

    Will be derived from observed data.

    Time frame: 24 months

  7. Trough concentration (Ctrough)

    Will be derived from observed data.

    Time frame: 24 months

  8. Terminal elimination half-life (T½)

    Will be estimated using non-compartmental methods and actual timepoints.

    Time frame: 24 months

  9. Clearance (CL)

    Will be estimated using non-compartmental methods and actual timepoints.

    Time frame: 24 months

07

Study locations

4 sites
  • South Texas Accelerated Research Therapeutics (START) Midwest
    Grand Rapids, Michigan 49503, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • NEXT Oncology
    San Antonio, Texas 78240, United States
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Mar 2022, 52 months.

Of 289 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's 52 months is close to that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2017
First posted
Oct 17, 2017
StartActual
Nov 20, 2017
Primary completionActual
Mar 23, 2022
CompletionActual
Mar 23, 2022
Last update
May 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03311412
Lead sponsor
Symphogen A/S
Responsible party
Sponsor
First posted
Oct 17, 2017
Start date
Nov 20, 2017
Primary completion
Mar 23, 2022
Completion
Mar 23, 2022
Last update
May 30, 2023

Study contacts

Lillian Siu, MD, FRCPC
principal investigator · Princess Margaret Cancer Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion